Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II PET-driven rituximab-chemotherapy study in young adults with high-risk CD20-positive diffuse large B-cell lymphoma
2007-000699-18Phase 2Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Apr 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rituximab, cyclophosphamide, doxorubicin, prednisone, vindesine and 8 more in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Complete response rate by PET after 4 induction cycles. Started Apr 2007; status: completed.
02
Drugs
rituximabcyclophosphamidedoxorubicinprednisonevindesine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2007-000699-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000699-18.